| EC359: a first-in-class small-molecule inhibitor for targeting oncogenic LIFR signaling in triple-negative breast cancer S Viswanadhapalli, Y Luo, GR Sareddy, B Santhamma, M Zhou, M Li, ... Molecular cancer therapeutics 18 (8), 1341-1354, 2019 | 59 | 2019 |
| LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer W Tang, K Ramasamy, SMA Pillai, B Santhamma, S Konda, ... Cell Death Discovery 7 (1), 216, 2021 | 19 | 2021 |
| SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance Z Liu, J Liu, B Ebrahimi, UP Pratap, Y He, KA Altwegg, W Tang, X Li, Z Lai, ... Breast Cancer Research 24 (1), 26, 2022 | 18 | 2022 |
| LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer M Li, S Viswanadhapalli, B Santhamma, UP Pratap, Y Luo, J Liu, ... Communications Biology 4 (1), 1235, 2021 | 17 | 2021 |
| Interaction of transcription factor AP‐2 gamma with proto‐oncogene PELP1 promotes tumorigenesis by enhancing RET signaling J Liu, Z Liu, M Li, W Tang, UP Pratap, Y Luo, KA Altwegg, X Li, Y Zou, ... Molecular oncology 15 (4), 1146-1161, 2021 | 15 | 2021 |
| Role of estrogen receptor coregulators in endocrine resistant breast cancer KA Altwegg, RK Vadlamudi Exploration of targeted anti-tumor therapy 2 (4), 385, 2021 | 13 | 2021 |
| PELP1 signaling contributes to medulloblastoma progression by regulating the NF‐κB pathway Y Luo, M Li, UP Pratap, S Viswanadhapalli, J Liu, PP Venkata, ... Molecular carcinogenesis 59 (3), 281-292, 2020 | 12 | 2020 |
| Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma UP Pratap, GR Sareddy, Z Liu, PP Venkata, J Liu, W Tang, KA Altwegg, ... Neuro-Oncology Advances 3 (1), vdab099, 2021 | 11 | 2021 |
| A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer KA Altwegg, S Viswanadhapalli, M Mann, D Chakravarty, S Krishnan, ... Cancer research 82 (20), 3830-3844, 2022 | 10 | 2022 |
| Global genomic and proteomic analysis identified critical pathways modulated by proto-oncogene PELP1 in TNBC Z Liu, KA Altwegg, J Liu, ST Weintraub, Y Chen, Z Lai, GR Sareddy, ... Cancers 14 (4), 930, 2022 | 6 | 2022 |
| Inhibition of LIFR blocks adiposity-driven endometrioid endometrial cancer growth L Blankenship, UP Pratap, X Yang, Z Liu, KA Altwegg, B Santhamma, ... Cancers 14 (21), 5400, 2022 | 5 | 2022 |
| PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis X Yang, Z Liu, W Tang, UP Pratap, AB Collier, KA Altwegg, R Gopalam, ... Molecular oncology 18 (9), 2136-2156, 2024 | 4 | 2024 |
| Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34 KA Altwegg, UP Pratap, Z Liu, J Liu, JR Sanchez, X Yang, B Ebrahimi, ... Breast Cancer Research and Treatment 200 (1), 151-162, 2023 | 3 | 2023 |
| HDAC inhibitors enhance ERβ expression and augment ERβ agonist mediated tumor suppression in glioblastoma UP Pratap, S Gangadhara, Z Liu, VP Venkata, J Liu, W Tang, K Altwegg, ... Neuro Oncol Adv 3 (1), vdab099, 2021 | 2 | 2021 |
| A novel small molecule targeting oncogenic PELP1 demonstrates anti-tumor activity in wild-type and mutant ER-positive breast cancer KA Altwegg, M Mann, D Chakravarty, Z Liu, J Liu, UP Pratap, B Ebrahimi, ... Cancer Research 82 (12_Supplement), 648-648, 2022 | 1 | 2022 |
| PELP1-TFAP2C crosstalk promotes endocrine resistance in breast cancer cells J Liu, S Viswanadhapalli, M Li, UP Pratap, W Tang, Z Liu, Y Luo, ... Cancer Research 80 (16_Supplement), 4371-4371, 2020 | 1 | 2020 |
| 778 Designing and utilizing a c-Rel specific bioassay in drug repurposing screen for HNSCC KA Altwegg, K King, D Blivis, T Voss, NJ Martinez, MJ Henderson, ... Journal of Investigative Dermatology 144 (8), S136, 2024 | | 2024 |
| Developing a drug repurposing screen for head and neck squamous cell carcinoma using a novel c-Rel bioassay KA Altwegg, KE King, D Blivis, TC Voss, NJ Martinez, WC Weinberg, ... Cancer Research 84 (6_Supplement), 3101-3101, 2024 | | 2024 |
| Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer S Viswanadhapalli, UP Pratap, B Ebrahimi, L Blankenship, J Joshi, Z Liu, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer S Viswanadhapalli, UP Pratap, B Ebrahimi, L Blankenship, J Joshi, Z Liu, ... Cancer Research 82 (4_Supplement), P5-10-01-P5-10-01, 2022 | | 2022 |
Ratna VadlamudiUT Health Science Center San Antonio在 uthscsa.edu 的电子邮件经过验证
